Reaction
Rectal Adenocarcinoma reporting signals
As of the last recalculation, Rectal Adenocarcinoma appears in 590 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is PANITUMUMAB (PRR 63.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Panitumumab | 27 | 63.7 | 63.8 |
| Regorafenib | 16 | 49.9 | 50.0 |
| Fluorouracil | 57 | 28.7 | 28.7 |
| Fluorouracil Cream, 0.5% | 55 | 28.0 | 28.0 |
| Oxaliplatin | 52 | 27.0 | 27.0 |
| Irinotecan Hydrochloride | 9 | 25.1 | 25.1 |
| Leucovorin Calcium | 12 | 22.6 | 22.6 |
| Cetuximab | 17 | 19.7 | 19.7 |
| Bevacizumab | 54 | 16.8 | 16.8 |
| Siponimod | 4 | 15.9 | 15.9 |